Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session.

most new drug applications do not pass Phase 3 trials, with all the positive sentiment tending to fade as capital raising and share dilution take center stage. VRTX has efficiently navigated the ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies ... meets each of this strategy's tests. Not all criteria in the below table receive ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies ... meets each of this strategy's tests. Not all criteria in the below table receive ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer yesterday. The company’s shares closed yesterday ...

NOW OPEN: 200 Charter Memberships to Benzinga Trade Alerts Vertex Pharmaceuticals Inc. VRTX shares are trading higher Friday following two major developments that strengthen its position in both ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is not on our list of 30 Most Popular ... One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149 • Bonus Reports ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports.